

Stahl's Essential Psychopharmacology

Prescriber's Guide

SIX IH EDITION

With the range of psychotropic drugs expanding and the usages of existing medications diversifying, we are pleased to present this very latest edition of what has become the indispensable formulary in psychopharmacology.

This new edition features seven new compounds as well as information about several new formulations of existing drugs. In addition, many important new indications are covered for existing drugs, as are updates to the profiles of the entire content and collection, including expansion of the sections on long-acting injectable formulations of antipsychotics.

With its easy-to-use, template-driven navigation system, *The Prescriber's Guide* combines evidence-based data with clinically informed advice to support everyone prescribing in the field of mental health.

Stephen M. Stahl is Adjunct Professor of Psychiatry at the University of California, San Diego, and Honorary Visiting Senior Fellow in Psychiatry at the University of Cambridge, UK. He has conducted various research projects awarded by the National Institute of Mental Health, Veterans Affairs, and the pharmaceutical industry. Author of more than 500 articles and chapters, Dr Stahl is also the author of the bestseller *Stahl's Essential Psychopharmacology*.



Stahl's Essential Psychopharmacology Prescriber's Guide

Stephen M. Stahl

University of California at San Diego, San Diego, California

Editorial assistant Meghan M. Grady

With illustrations by Nancy Muntner





CAMBRIDGEUNIVERSITY PRESS

University Printing House, Cambridge CB2 8BS, United Kingdom One Liberty Plaza, 20th Floor, New York, NY 10006, USA 477 Williamstown Road, Port Melbourne, VIC 3207, Australia 4843/24, 2nd Floor, Ansari Road, Daryaganj, Delhi – 110002, India 79 Anson Road, #06-04/06, Singapore 079906

Cambridge University Press is part of the University of Cambridge.

It furthers the University's mission by disseminating knowledge in the pursuit of education, learning, and research at the highest international levels of excellence.

www.cambridge.org

Information on this title: www.cambridge.org/9781316618134

© Stephen M. Stahl 2005, 2006, 2009, 2011, 2014, 2017

This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2005 Revised and updated edition published 2006 Third edition published 2009 Fourth edition published 2011 Fifth edition published 2014 Sixth edition published 2017

Printed in the United Kingdom by Clays, St Ives plc

A catalog record for this publication is available from the British Library.

ISBN 978-1-316-61813-4 Paperback ISBN 978-1-108-40488-4 Spiral

Additional resources for this publication at www.stahlonline.org

Every effort has been made in preparing this book to provide accurate and up-to-date information that is in accord with accepted standards and practice at the time of publication. Although case histories are drawn from actual cases, every effort has been made to disguise the identities of the individuals involved. Nevertheless, the authors, editors, and publishers can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors, and publishers therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use.

Cambridge University Press has no responsibility for the persistence or accuracy of URLs for external or third-party Internet Web sites referred to in this publication, and does not guarantee that any content on such Web sites is, or will remain, accurate or appropriate.



Contents

	Introduction	ix
	List of icons	xiii
1	acamprosate	1
2	agomelatine	5
3	alprazolam	11
4	amisulpride	17
5	amitriptyline	25
6	amoxapine	33
7	amphetamine (d)	39
8	amphetamine (d,l)	45
9	aripiprazole	53
0	armodafinil	65
1	asenapine	71
2	atomoxetine	77
3	benztropine	83
4	blonanserin	87
5	brexpiprazole	93
6	buprenorphine	101
7	bupropion	107
8	buspirone	113
9	caprylidene	117
0.2	carbamazepine	121
21	cariprazine	127
2.2	chlordiazepoxide	133
23	chlorpromazine	139
24	citalopram	145
25	clomipramine	151
26	clonazepam	159
27	clonidine	165
28	clorazepate	171
9	clozapine	177
30	cyamemazine	187
31	desipramine	193
32	desvenlafaxine	201
3	dextromethorphan	207
34	diazepam	211



More Information

35	diphenhydramine	217
36	disulfiram	221
37	donepezil	225
38	dothiepin	231
39	doxepin	237
40	duloxetine	245
41	escitalopram	251
42	estazolam	257
43	eszopiclone	261
44	flibanserin	265
45	flumazenil	269
46	flunitrazepam	273
47	fluoxetine	277
48	flupenthixol	283
49	fluphenazine	289
50	flurazepam	297
51	fluvoxamine	301
52	gabapentin	307
53	galantamine	313
54	guanfacine	319
55	haloperidol	323
56	hydroxyzine	331
57	iloperidone	335
58	imipramine	341
59	isocarboxazid	349
60	ketamine	357
61	lamotrigine	361
62	levetiracetam	369
63	levomilnacipran	373
64	lisdexamfetamine	379
65	lithium	385
66	lofepramine	391
67	loflazeptate	397
68	lorazepam	403
69	lorcaserin	409
70	loxapine	413
71	lurasidone	419
72	maprotiline	427
73	memantine	435
74	mesoridazine	439



More Information

75	methylfolate (l)	445
76	methylphenidate (d)	449
77	methylphenidate (d,l)	455
78	mianserin	463
79	midazolam	469
80	milnacipran	473
81	mirtazapine	479
82	moclobemide	485
83	modafinil	491
84	molindone	497
85	nalmefene	501
86	naltrexone	505
87	naltrexone-bupropion	509
88	nefazodone	513
89	nortriptyline	519
90	olanzapine	527
91	oxazepam	537
92	oxcarbazepine	543
93	paliperidone	549
94	paroxetine	561
95	perospirone	569
96	perphenazine	573
97	phenelzine	579
98	phentermine-topiramate	585
99	pimavanserin	589
100	pimozide	593
101	pipothiazine	599
102	prazosin	605
103	pregabalin	609
104	propranolol	613
105	protriptyline	617
106	quazepam	623
107	quetiapine	627
108	ramelteon	635
109	reboxetine	639
110	risperidone	645
111	rivastigmine	655
112	selegiline	661
113	sertindole	671
114	sertraline	677

vii



115	sodium oxybate	685
116	sulpiride	689
117	suvorexant	695
118	tasimelteon	699
119	temazepam	703
120	thioridazine	707
121	thiothixene	713
122	tiagabine	719
123	tianeptine	725
124	topiramate	729
125	tranylcypromide	735
126	trazodone	741
127	triazolam	747
128	trifluoperazine	751
129	trihexyphenidyl	757
130	triiodothyronine	761
131	trimipramine	765
132	valproate	773
133	varenicline	781
134	venlafaxine	785
135	vilazodone	791
136	vortioxetine	797
137	zaleplon	803
138	ziprasidone	807
139	zolpidem	815
140	zonisamide	819
141	zopiclone	823
142	zotepine	827
143	zuclopenthixol	833
	Index by drug name	839
	Index by use	855
	Index by class	863
	Abbreviations	866



Introduction

This Guide is intended to complement Stahl's Essential Psychopharmacology. Stahl's Essential Psychopharmacology emphasizes mechanisms of action and how psychotropic drugs work upon receptors and enzymes in the brain. This Guide gives practical information on how to use these drugs in clinical practice.

It would be impossible to include all available information about any drug in a single work, and no attempt is made here to be comprehensive. The purpose of this *Guide* is instead to integrate the art of clinical practice with the science of psychopharmacology. That means including only essential facts in order to keep things short. Unfortunately that also means excluding less critical facts as well as extraneous information, which may nevertheless be useful to the reader but would make the book too long and dilute the most important information. In deciding what to include and what to omit, the author has drawn upon common sense and 30 years of clinical experience with patients. He has also consulted with many experienced clinicians and analyzed the evidence from controlled clinical trials and regulatory filings with government agencies.

In order to meet the needs of the clinician and to facilitate future updates of this *Guide*, the opinions of readers are sincerely solicited. Feedback can be emailed to feedback@neiglobal.com. Specifically, are the best and most essential psychotropic drugs included here? Do you find any factual errors? Are there agreements or disagreements with any of the opinions expressed here? Are there suggestions for any additional tips or pearls for future editions? Any and all suggestions and comments are welcomed

All of the selected drugs are presented in the same design format in order to facilitate rapid access to information. Specifically, each drug is broken down into five sections, each designated by a unique color background: ■ therapeutics, ■ side effects, ■ dosing and use, ■ special populations, and ■ the art of psychopharmacology, followed by key references.

Therapeutics covers the brand names in major countries; the class of drug; what it is commonly prescribed and approved for by the United States Food and Drug Administration (FDA); how the drug works; how long it takes to work; what to do if it works or if it doesn't work; the best augmenting combinations for partial response or treatment resistance; and the tests (if any) that are required.

Side effects explains how the drug causes side effects; gives a list of notable, life-threatening, or dangerous side effects; gives a specific rating for weight gain or sedation; and gives advice about how to handle side effects, including best augmenting agents for side effects.

Dosing and use gives the usual dosing range; dosage forms; how to dose and dosing tips; symptoms of overdose; long-term use; if habit forming, how to stop; pharmacokinetics; drug interactions; when not to use; and other warnings or precautions.

Special populations gives specific information about any possible renal, hepatic, and cardiac impairments, and any precautions to be taken for treating the elderly, children, adolescents, and pregnant and breast-feeding women.

The art of psychopharmacology gives the author's opinions on issues such as the potential advantages and disadvantages of any one drug, the primary target symptoms, and clinical pearls to get the best out of a drug.



In addition, drugs for which switching between medications can be complicated have a special section called The Art of Switching, which includes clinical pearls and graphical representations to help guide the switching process.

There is a list of icons used in this *Guide* following this Introduction and at the back of the *Guide* are several indices. The first is an index by drug name, giving both generic names (uncapitalized) and trade names (capitalized and followed by the generic name in parentheses). The second is an index of common uses for the generic drugs included in the *Guide* and is organized by disorder/symptom. Agents that are approved by the FDA for a particular use are shown in bold. The third index is organized by drug class and lists all the agents that fall within each particular class. In addition to these indices there is a list of abbreviations.

Readers are encouraged to consult standard references¹ and comprehensive psychiatry and pharmacology textbooks for more in-depth information. They are also reminded that the art of psychopharmacology section is the author's opinion.

It is strongly advised that readers familiarize themselves with the standard use of these drugs before attempting any of the more exotic uses discussed, such as unusual drug combinations and doses. Reading about both drugs before augmenting one with the other is also strongly recommended. Today's psychopharmacologist should also regularly track blood pressure, weight, and body mass index for most of his or her patients. The dutiful clinician will also check out the drug interactions of non-central nervous system (CNS) drugs with those that act in the CNS, including any prescribed by other clinicians.

Certain drugs may be for experts only and might include clozapine, thioridazine, pimozide, nefazodone, mesoridazine, and monoamine oxidase (MAO) inhibitors, among others. Off-label uses not approved by the FDA and inadequately studied doses or combinations of drugs may also be for the expert only, who can weigh risks and benefits in the presence of sometimes vague and conflicting evidence. Pregnant or nursing women, or people with two or more psychiatric illnesses, substance abuse, and/or a concomitant medical illness may be suitable patients for the expert only. Controlled substances also require expertise. Use your best judgment as to your level of expertise and realize that we are all learning in this rapidly advancing field. The practice of medicine is often not so much a science as it is an art. It is important to stay within the standards of medical care for the field, and also within your personal comfort zone, while trying to help extremely ill and often difficult patients with medicines that can sometimes transform their lives and relieve their suffering.

Finally, this book is intended to be genuinely helpful for practitioners of psychopharmacology by providing them with the mixture of facts and opinions selected by the author. Ultimately, prescribing choices are the reader's responsibility. Every effort has been made in preparing this book to provide accurate and up-to-date information in accord with accepted standards and practice at the time of publication. Nevertheless, the psychopharmacology field is evolving rapidly and the author and publisher make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. Furthermore, the author and publisher disclaim any responsibility for the

¹ For example, Physician's Desk Reference and Martindale: The Complete Drug Reference.



continued currency of this information and disclaim all liability for any and all damages, including direct or consequential damages, resulting from the use of information contained in this book. Doctors recommending and patients using these drugs are strongly advised to pay careful attention to, and consult information provided by, the manufacturer.



List of icons



alcohol dependence treatment



alpha adrenergic blocker



alpha 2 agonist



anticonvulsant



antihistamine



antiparkinson/anticholinergic



benzodiazepine



beta blocker



cholinesterase inhibitor



conventional antipsychotic



dopamine stabilizer



flibanserin



lithium



lorcaserin



medical food

xiii





l-methylfolate



modafinil (wake-promoter)



monoamine oxidase inhibitor



naltrexone-bupropion



nefazodone (serotonin antagonist/reuptake inhibitor)



nicotinic partial agonist



N-methyl-D-aspartate antagonist



noradrenergic and specific serotonergic antidepressant



norepinephrine and dopamine reuptake inhibitor



pimavanserin



sedative-hypnotic



selective norepinephrine reuptake inhibitor



selective serotonin reuptake inhibitor



serotonin-dopamine antagonist

xiv





serotonin and norepinephrine reuptake inhibitor



serotonin 1A partial agonist



serotonin partial agonist reuptake inhibitor



sodium oxybate



stimulant



suvorexant



tasimelteon



thyroid hormone



topiramate/phentermine



trazodone (serotonin antagonist/reuptake inhibitor)



tricyclic/tetracyclic antidepressant



vortioxetine



How the drug works, mechanism of action



Best augmenting agents to add for partial response or treatment resistance



Life-threatening or dangerous side effects











Weight Gain: Degrees of weight gain associated with the drug, with unusual signifying that weight gain has been reported but is not expected; not unusual signifying that weight gain occurs in a significant minority; common signifying that many experience weight gain and/or it can be significant in amount; and problematic signifying that weight gain occurs frequently, can be significant in amount, and may be a health problem in some patients









Sedation: Degrees of sedation associated with the drug, with unusual signifying that sedation has been reported but is not expected; not unusual signifying that sedation occurs in a significant minority; common signifying that many experience sedation and/or it can be significant in amount; and problematic signifying that sedation occurs frequently, can be significant in amount, and may be a health problem in some patients



Tips for dosing based on the clinical expertise of the author



Drug interactions that may occur



Warnings and precautions regarding use of the drug



Dosing and other information specific to children and adolescents



Information regarding use of the drug during pregnancy



Clinical pearls of information based on the clinical expertise of the author



The art of switching



Suggested reading

xvi